10.2967/jnmt.117.227892 [DOI] [PubMed] [Google Scholar] 29.Bharucha AE, Camilleri M, Veil E, Burton D, Zinsmeister AR (2013) Comprehensive assessment of gastric emptying with a stable isotope breath test
Having ongoing support from your provider and a care team is also a plus
Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself
This approach allows Virginia patients to access professional weight loss support conveniently and responsibly
This collaboration is the latest in a series of efforts to partner across the ecosystem, and deploy multimodal data to advance a deeper understanding of biology
Happy hour There has been a massive change in my drinking habits
